Table 3.

Time-varying analysis for recurrent VTE, major bleeding, and all-cause mortality in the overall study population

Variable	Recurrent VTE		Major bleeding		All-cause mortality
	Univariable	Multivariable	Univariable	Multivariable	Univariable	Multivariable
Anticoagulant treatment	0.35 (0.23-0.52)	0.42 (0.27-0.64)	0.38 (0.24-0.58)	0.47 (0.30-0.74)	0.17 (0.13-0.23)	0.23 (0.17-0.31)
Age, 1-y increase	1.03 (1.01-1.04)	1.02 (1.00-1.03)	1.03 (1.02-1.05)	1.03 (1.01-1.04)	1.04 (1.03-1.05)	1.02 (1.01-1.03)
Sex, male	1.78 (1.16-2.74)	1.54 (1.00-2.37)	1.16 (0.75-1.79)	–	1.15 (0.89-1.49)	–
Cirrhosis	1.62 (1.04-2.52)	1.10 (0.70-1.73)	2.87 (1.85-4.45)	1.92 (1.21-3.05)	1.57 (1.18-2.09)	0.95 (0.71-1.27)
Solid cancer	2.78 (1.88-4.12)	2.02 (1.35-3.04)	1.70 (1.09-2.67)	1.22 (0.77-1.92)	12.92 (9.46-17.65)	8.68 (6.24-12.07)
Myeloproliferative neoplasm	0.31 (0.10-1.00)	–	0.86 (0.38-1.98)	–	0.19 (0.07-0.51)	0.96 (0.34-2.69)
Transient or persistent nonmalignant risk factor*	0.70 (0.42-1.16)	–	0.45 (0.23-0.87)	0.63 (0.35-1.25)	0.34 (0.22-0.52)	0.50 (0.32-0.77)

Values are expressed as HR (95% CI). Only covariates that were associated on univariable analysis were tested in multivariable analysis.

^*Risk factors included any of the following: pregnancy, contraceptive, hormonal therapy, recent surgery, and inflammatory bowel disease.